Ibrutinib appears safe, effective against chronic lymphocytic leukemia
Ibrutinib, which targets the Bruton’s tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
Diagnosis & Disease Information
Nanoparticles show potential in photothermal therapy for colorectal cancer
Electrically-conductive polymers, commonly used in solar energy applications, have been modified so that infrared light causes them to generate heat that can be used to kill colorectal cancer cells.
Abnormal gene that launches rare childhood leukemia is identified
A fusion gene that is responsible for 30% of a rare subtype of childhood leukemia with an extremely poor prognosis has been identified. This finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic leukemia cases in children.
Individualized molecular portraits can match patients to clinical trials
French researchers are taking advantage of the progress in genetic and molecular profiling to analyze the make-up of the tumors of individual cancer patients and then using the information to assign patients to particular treatments and phase I clinical trials.
Advanced melanoma controlled with chemotherapy/ immunotherapy combo
A combination of chemotherapy and immunotherapy appears to be a labor-intensive but feasible treatment for persons with metastatic melanoma.
Vaccine for existing HPV infection may thwart cervical cancer
A therapeutic vaccine for women who are already harboring human papillomavirus (HPV) appeared to fight cervical cancer in a small, phase 1 study.
Melanoma cells stay active by staying in the dark about drug damage
Melanoma cells are able to build up tolerance to chemotherapy by means of a genetic pathway that inhibits their detection of DNA damage.
Potential targets to treat squamous cell lung cancer
Many potential targets for squamous cell lung cancer (SCLC) have been identified by The Cancer Genome Atlas (TCGA). The study involved a team of researchers from throughout the United States, plus the British Columbia Cancer Agency in Vancouver, British Columbia, Canada.
Injectable trastuzumab quicker than IV version
Subcutaneous delivery of trastuzumab (Herceptin) appears to be as safe and effective as the much more time-consuming intravenous system.
FDA Update – July/August 2012
News about pertuzumab injection (Perjeta); ondansetron (Zofran); carfilzomib (Kyprolis); Therascreen KRAS RGQ PCR Kit; Prostate Health Index (phi); and Prepopik
- Loading...
Loading...
Next post in In the News
Loading... 
Loading...